BR9912327A - Inibidores da uroquinase - Google Patents

Inibidores da uroquinase

Info

Publication number
BR9912327A
BR9912327A BR9912327-4A BR9912327A BR9912327A BR 9912327 A BR9912327 A BR 9912327A BR 9912327 A BR9912327 A BR 9912327A BR 9912327 A BR9912327 A BR 9912327A
Authority
BR
Brazil
Prior art keywords
urokinase inhibitors
urokinase
inhibitors
amidino
metastasis
Prior art date
Application number
BR9912327-4A
Other languages
English (en)
Other versions
BR9912327B1 (pt
Inventor
Olaf Wilhelm
Viktor Magdolen
Joerg Stuerzebecher
John Foekens
Verena Lutz
Original Assignee
Wilex Biotechnology Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9912327(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wilex Biotechnology Gmbh filed Critical Wilex Biotechnology Gmbh
Publication of BR9912327A publication Critical patent/BR9912327A/pt
Publication of BR9912327B1 publication Critical patent/BR9912327B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0404Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205Radicals derived from carbonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Patente de invenção para: <B>"INIBIDORES DA UROQUINASE"<D>. A invenção refere-se ao uso de derivados da 3-amidino-fenil-alanina como inibidores de uroquinase para o tratamento de tumores malignos e da formação de metástase.
BRPI9912327-4B1A 1998-07-20 1999-07-20 Inibidores da uroquinase BR9912327B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98113519 1998-07-20
PCT/EP1999/005145 WO2000004954A2 (de) 1998-07-20 1999-07-20 Neue urokinase-inhibitoren

Publications (2)

Publication Number Publication Date
BR9912327A true BR9912327A (pt) 2001-05-02
BR9912327B1 BR9912327B1 (pt) 2013-11-12

Family

ID=8232314

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9912327-4B1A BR9912327B1 (pt) 1998-07-20 1999-07-20 Inibidores da uroquinase

Country Status (12)

Country Link
US (2) US6624169B1 (pt)
EP (2) EP1264828B1 (pt)
JP (1) JP4603162B2 (pt)
AT (2) ATE264103T1 (pt)
AU (1) AU754958B2 (pt)
BR (1) BR9912327B1 (pt)
CA (1) CA2338073C (pt)
DE (2) DE59903981D1 (pt)
ES (2) ES2189455T3 (pt)
MX (1) MXPA01000553A (pt)
PT (1) PT1264828E (pt)
WO (1) WO2000004954A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59806475D1 (de) * 1998-09-18 2003-01-09 Pentapharm Ag Basel Urokinase-inhibitoren
DE10013715A1 (de) * 2000-03-20 2001-09-27 Wilex Biotechnology Gmbh Hochselektive Inhibitoren des Urokinase-Plasminogenaktivators
DE10029014A1 (de) * 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
WO2002074756A2 (de) 2001-03-21 2002-09-26 Pentapharm Ag Urokinase-inhibitoren
US7838560B2 (en) 2002-03-11 2010-11-23 The Medicines Company (Leipzig) Gmbh Urokinase inhibitors, production and use thereof
DE10225876A1 (de) * 2002-06-11 2003-12-24 Wilex Ag Guanidinophenylalaninverbindungen als Urokinase-Inhibitoren
DE10233632A1 (de) * 2002-07-24 2004-02-05 Wilex Ag Formulierungen von Phenylalanin-Derivaten
WO2004011449A2 (de) * 2002-07-25 2004-02-05 Wilex Ag Verfahren zur herstellung von phenylalanin-derivaten
DE10238048A1 (de) * 2002-07-25 2004-02-05 Wilex Ag Verfahren zur Herstellung von Phenylalanin-Derivaten
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
DE10322191B4 (de) * 2003-05-16 2014-02-27 The Medicines Company (Leipzig) Gmbh N-sulfonylierte Aminosäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE10323898A1 (de) 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
DE102004045720A1 (de) * 2004-09-21 2006-03-23 Wilex Ag Stabile Dosierungsform von Phenylalanin-Derivaten
CA2612262A1 (en) 2005-06-24 2006-12-28 Wilex Ag Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
WO2011150245A2 (en) * 2010-05-26 2011-12-01 Expression Pathology, Inc. Urokinase-type plasminogen activator protein/plasminogen activator inhibitor type-1 protein-selected reaction monitoring assay
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
JP6755881B2 (ja) 2015-03-30 2020-09-16 サニーブルック リサーチ インスティテュート がんを処置するための方法
KR101888249B1 (ko) * 2015-09-24 2018-08-13 주식회사 엘지화학 화합물 및 이를 포함하는 유기 전자 소자
RU2727474C2 (ru) * 2015-10-06 2020-07-21 Редхилл Байофарма Лтд. Виды комбинированной терапии для лечения рака
BR112022017923A2 (pt) 2020-03-10 2022-10-18 Redhill Biopharma Ltd Tratamento de infecção por coronavírus
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE460667B (sv) 1979-09-20 1989-11-06 Nippon Chemiphar Co Cyklohexankarboxylsyraderivat, foerfarande foer framstaellning daerav samt naemnda derivat foer terapeutisk anvaendning
EP0183271B1 (en) 1984-11-30 1990-05-16 Shosuke Okamoto Lysin derivative and proteinase inhibitor
EP0511347A1 (de) * 1990-11-15 1992-11-04 Pentapharm A.G. Meta-substituierte phenylalanin-derivate
HUT68042A (en) 1993-02-10 1995-03-22 Pentapharm Ag Piperazides of substituted phenylalanine derivates as thrombin inhibitors
US5550213A (en) 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
AU3107795A (en) * 1994-08-09 1996-03-07 Pentapharm Ag Inhibitors of the benzamidine type
DE9418185U1 (de) * 1994-11-12 1995-02-23 Richard Wolf Gmbh, 75438 Knittlingen Behälter für medizinische Instrumente
CH689611A5 (de) * 1995-03-01 1999-07-15 Pentapharm Ag Urokinase-Inhibitoren.
DE59806475D1 (de) * 1998-09-18 2003-01-09 Pentapharm Ag Basel Urokinase-inhibitoren

Also Published As

Publication number Publication date
US6680320B2 (en) 2004-01-20
DE59903981D1 (de) 2003-02-13
JP2002521348A (ja) 2002-07-16
DE59909210D1 (de) 2004-05-19
JP4603162B2 (ja) 2010-12-22
ATE230599T1 (de) 2003-01-15
WO2000004954A2 (de) 2000-02-03
AU5161599A (en) 2000-02-14
ES2189455T3 (es) 2003-07-01
EP1264828B1 (de) 2004-04-14
EP1098651B1 (de) 2003-01-08
CA2338073C (en) 2010-09-21
ES2219607T3 (es) 2004-12-01
EP1264828A1 (de) 2002-12-11
PT1264828E (pt) 2004-08-31
EP1098651A2 (de) 2001-05-16
AU754958B2 (en) 2002-11-28
MXPA01000553A (es) 2002-04-24
CA2338073A1 (en) 2000-02-03
ATE264103T1 (de) 2004-04-15
US6624169B1 (en) 2003-09-23
US20030013723A1 (en) 2003-01-16
BR9912327B1 (pt) 2013-11-12
WO2000004954A3 (de) 2000-06-22

Similar Documents

Publication Publication Date Title
BR9912327A (pt) Inibidores da uroquinase
MY129409A (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
PT1193270E (pt) Pirrolobenzodiazepinas
AR023777A1 (es) Nuevos compuestos
ATE231872T1 (de) Thiazolopyrimidinderivate
BR9805544A (pt) Uso de um composto.
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
DE60106954D1 (de) Resorcin-derivate
BR9711586A (pt) Compostos e uso dos mesmo
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
BRPI0110506B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
BR9913533A (pt) Processos para tratar hipertensão e composições para uso nos mesmos
EP1305322A4 (en) LIPOPHILIC MOLECULE DERIVATIVES AND CORRESPONDING USES THEREOF
SE9801494D0 (sv) Novel use
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
BR0012675A (pt) Uso de inibidores de il-18
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
BR0110902A (pt) Inibidores de mmp-9/mmp-2
BR0112600A (pt) Compostos calcilìticos
NO20005548L (no) Mykobakterieinhibitorer
BR0114856A (pt) Combinação compreendendo camptotecina e um derivado de estilbeno para o tratamento de câncer
BG105252A (en) Isoquinolines as urokinase inhibitors
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: WILEX AG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080117818/RJ DE 08/09/2008.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2236 DE 12.11.2013, QUANTO AO NOME E ENDERECO DO TITULAR

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/495 (2006.01), A61K 51/04 (2006.0

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2523 DE 14-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.